Free Trial

Fate Therapeutics (FATE) Stock Price, News & Analysis

Fate Therapeutics logo
$1.07 -0.03 (-2.73%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.06 -0.01 (-0.47%)
As of 08/1/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fate Therapeutics Stock (NASDAQ:FATE)

Key Stats

Today's Range
$1.06
$1.11
50-Day Range
$1.04
$1.67
52-Week Range
$0.66
$4.66
Volume
767,002 shs
Average Volume
1.32 million shs
Market Capitalization
$122.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.83
Consensus Rating
Hold

Company Overview

Fate Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

FATE MarketRank™: 

Fate Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 189th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fate Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Fate Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.63) to ($1.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fate Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fate Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fate Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Fate Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.25% of the outstanding shares of Fate Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Fate Therapeutics has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Fate Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fate Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Fate Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.25% of the outstanding shares of Fate Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Fate Therapeutics has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Fate Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving.
  • News Sentiment

    Fate Therapeutics has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Fate Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fate Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.51% of the stock of Fate Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fate Therapeutics' insider trading history.
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
See More Headlines

FATE Stock Analysis - Frequently Asked Questions

Fate Therapeutics' stock was trading at $1.65 at the beginning of the year. Since then, FATE shares have decreased by 35.2% and is now trading at $1.07.

Fate Therapeutics, Inc. (NASDAQ:FATE) released its quarterly earnings data on Tuesday, May, 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. The biopharmaceutical company earned $1.63 million during the quarter, compared to analyst estimates of $1.18 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 47.17% and a negative net margin of 1,318.93%.

Fate Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.19%), Public Employees Retirement System of Ohio (0.10%) and Vanguard Personalized Indexing Management LLC (0.06%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, Bahram Valamehr, John Mendlein, Jerome Charles Bressi, Cindy Tahl, Yu-Waye Chu, Edward J Dulac III, Brian T Powl and Yuan Xu.
View institutional ownership trends
.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

Last Earnings
5/13/2025
Today
8/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FATE
CIK
1434316
Fax
N/A
Employees
550
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$2.00
Potential Upside/Downside
+258.3%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$186.26 million
Net Margins
-1,318.93%
Pretax Margin
-1,318.93%
Return on Equity
-47.17%
Return on Assets
-34.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.81
Quick Ratio
8.81

Sales & Book Value

Annual Sales
$13.63 million
Price / Sales
9.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.80 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
114,600,000
Free Float
108,289,000
Market Cap
$122.62 million
Optionable
Optionable
Beta
2.24

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:FATE) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners